Differential effect of platelet-rich plasma and fetal calf serum on bone marrow-derived human mesenchymal stromal cells expanded in vitro

Journal of Tissue Engineering and Regenerative Medicine

Volumn 5, Issue 8, 2011, Pages 648-654

  Goedecke, Anja ^a,b   Wobus, Manja ^a   Krech, Mathias ^a,b   Münch, Nadine ^a,b   Richter, Katja ^a,b   Hölig, Kristina ^a   Bornhauser, Martin ^a,b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

Bone marrow; Fetal calf serum; Mesenchymal stromal cells; Migration; Platelet rich plasma; SDF 1

Indexed keywords

BONE; CELL CULTURE; EXPANSION; FLOWCHARTING; PLASMA (HUMAN); PLATELETS;

BONE MARROW; CELL-BASED THERAPY; CLINICAL APPLICATION; DIFFERENTIAL EFFECT; FOETAL CALF SERUMS; IN-VITRO; MESENCHYMAL STROMAL CELLS; MIGRATION; PLATELET RICH PLASMA; SDF-1;

STEM CELLS;

5' NUCLEOTIDASE; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; CD14 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CDW90 ANTIGEN; ENDOGLIN; LYMPHOCYTE ANTIGEN; STROMAL CELL DERIVED FACTOR 1ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; CYTOKINE RELEASE; FETAL CALF SERUM; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MESENCHYMAL STEM CELL; PHENOTYPE; PRIORITY JOURNAL; STEM CELL EXPANSION; SUPERNATANT; THROMBOCYTE RICH PLASMA;

EID: 79960541694     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.359     Document Type: Article

References (26)

1. Bartholomew A, Sturgeon C, Siatskas M, et al. 2002; Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30: 42-48.
2. Broxmeyer HE, Cooper S, Kohli L, et al. 2003; Transgenic expression of stromal cell-derived factor-1/CXC chemokine ligand 12 enhances myeloid progenitor cell survival/antiapoptosis in vitro in response to growth factor withdrawal and enhances myelopoiesis in vivo. J Immunol 170: 421-429.
3. Castro-Malaspina H, Gay RE, Resnick G, et al. 1980; Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood 56: 289-301.
4. Di Nicola M, Carlo-Stella C, Magni M, et al. 2002; Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or non-specific mitogenic stimuli. Blood 99: 3838-3843.
5. Dominici M, Le Blanc K, Müller I, et al. 2006; Minimal criteria for defining multipotent mesenchymal stromal cells. The international society therapy position statement. Cytotherapy 8: 315-317.
6. Doucet C, Ernou I, ZHang Y, et al. 2005; Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol 205: 228-236.
7. Gan Y, Dai K, Zhang P, et al. 2008; The clinical use of enriched bone marrow stem cells combined with porous β-tricalcium phosphate in posterior spinal fusion. Biomaterials 29: 3973-3982.
8. Gao H, Priebe W, Glod J, et al. 2009; Activation of signal transducers and activators of transcription 3 and focal adhesion kinase by stromal cell-derived factor 1 is required for migration of human mesenchymal stem cells in response to tumor cell-conditioned medium. Stem cells 27: 857-865.
9. Ko IK, Kim BG, Awadallah A, et al. 2010; Targeting improves MSC treatment of inflammatory bowel disease. Mol Ther (in press).
10. Koç ON, Gerson SL, Cooper BW, et al. 2000; Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 18: 307-316.
11. Kocaoemer A, Kern S, Klueter H, et al. 2007; Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells 25: 1270-1278.
12. + cell proliferation in synergy with cytokines: possible role in progenitor survival. Blood 95: 756-768.
13. Le Blanc K, Frassoni F, Ball L, et al. 2008; Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371: 1579-1586.
14. Le Blanc K, Rasmusson I, Sunberg B, et al. 2004; Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363: 1439-1441.
15. Le Blanc K, Samuelsson H, Gustafsson, et al. 2007; Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 21: 1733-1738.
16. Lee KD, Kuo TK, Whang-Peng J, et al. 2004; In vitro hepatic differentiation of human mesenchymal stem cells. Hepatology 40: 1275-1284.
17. Muller I, Kordowich S, Holzwarth C, et al. 2006; Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. Cytotherapy 8: 437-444.
18. Munoz-Elias G, Woodbury D, Black IB. 2003; Marrow stromal cells, mitosis and neuronal differentiation: stem cell and precursor functions Stem Cells 21: 437-448.
19. Oswald J, Boxberger S, Jorgensen B, et al. 2004; Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 22: 377-384.
20. Picinich SC, Glod JW, Banerjee D. 2010; Protein kinase Cζ regulates interleukin-8-mediated stromal-derived factor-1 expression and migration of human mesenchymal stromal cells. Exp Cell Res 316: 593-602.
21. Pittenger MF, Mackay AM, Beck SC, et al. 1999; Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147.
22. Salvadè A, Della Mina P, Gaddi D, et al. 2009; Characterization of platelet lysate (PL)-cultured mesenchymal stromal cells (MSCs) and their potential use in tissue-engineered osteogenic devices for the treatment of bone defects. Tissue Eng C Methods 1: 201-214.
23. Shi M, Li J, Liao L, et al. 2007; Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. Haematologica 92: 897-904.
24. Son BR, Marquez-Curtis LA, Kucia M, et al. 2006; Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells 24: 1254-1264.
25. Sordi V, Malosio ML, Marchesi F, et al. 2005; Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 106: 419-427.
26. von Bonin M, Stölzel F, Goedecke A, et al. 2009; Treatment of refractory acute GvHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transpl 43: 245-251.